STAT+: Fatal gene-editing trial in China raises ethics and oversight questions

URL has been copied successfully!

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, a win for RFK Jr., as an FDA panel narrowly voted in favor of allowing compounding pharmacies to produce certain unregulated peptides. Also, in heart-wrenching detail, Science writes of the six-year-old girl who died in China after receiving an experimental, brain-directed CRISPR therapy.

The Readout’s taking a summer break next week, so we’ll see you in August!

Continue to STAT+ to read the full story…

Please follow us:
Follow by Email
X (Twitter)
Whatsapp
LinkedIn
Copy link

This post was originally published here